Emergent BioSolutions | EBS - Net Income


Emergent BioSolutions reported $-261.3M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD 16.29M 15.79M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amarin USD -1.22M 6.51M Dec/2025
ANI Pharmaceuticals USD 35.15M 10.44M Sep/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Exelixis USD 218.1M 6.04M Sep/2026
Glaxosmithkline GBP 1.54B 194M Sep/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Lonza CHF 426M 119M Jun/2025
Merck USD 5.07B 6.4B Sep/2026
Moderna USD 162M 944M Sep/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Pacira USD 325.3M 320.65M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
United Therapeutics USD 258.6M 74.4M Sep/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024